Background:

Lansoprazole sodium is a proton-pump inhibitor (PPI) and also can inhibit cytochrome P450 [1].

Lansoprazole sodium is a substituted benzimidazole and has been widely used as acid inhibitory agent for treatment of disorders related to gastric acid secretion. Lansoprazole sodium has been exhibited to inhibit stomach acid by blocking the H+/K+ATPase system at the secretory surface of gastric parietal cells. As the human P450 enzymes including CYP2C9,2C19, 2D6 and 3A4, in addition, Lansoprazole sodium has been reported to have the competitively inhibitory effect on the activity of CYP2C9 in HLM with a Ki value of 21μM. Lansoprazole sodium has been found to be potent CYP2C19 inhibitor with a Ki value of about 1μM in both HLM and rCYP2C19 tests. Besides, Lansoprazole sodium has been revealed to inhibit the activities if CYP2D6 and CYP3A4 with IC50 values of both>200μM [1].

参考文献:
[1] Li XQ1, Andersson TB, Ahlstr?m M, Weidolf L.Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7.